Can a peptide tame type 1 diabetes?

NCT ID NCT05428943

Completed Disease control Sponsor: Op-T LLC Source: ClinicalTrials.gov ↗

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This trial is testing an investigational drug called OPT101 in adults with type 1 diabetes. The goal is to see if it is safe and how it affects the immune system. Participants will receive multiple doses of the drug, and researchers will monitor for side effects and measure drug levels in the blood.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: OPT101, a peptide derived from mouse CD154
What this could lead to: If successful, this could lead to a new treatment that helps manage type 1 diabetes by modulating the immune system.
What could go wrong: This is an early-phase trial with a small number of participants, so safety and effectiveness are not yet established. The peptide may not produce the desired immune effects or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus type 1 diabetes mellitus 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS, TYPE 1

Contacts and locations

Locations

Diablo Clinical Research Center

Walnut Creek, California, 94598, United States
Rainier Clinical Research Center

Renton, Washington, 98057, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.